Ramp Up In Opdivo And Eliquis Sales Bolsters Bristol-Myers Squibb’s Q1 Earnings

By Trefis Team, Contributor Bristol-Myers Squibb recently posted its Q1 results, which were more or less in line with street estimates. The company’s overall revenues grew 5%, led by a continued ramp up in Opdivo and Eliquis sales. The bottom line benefited from a lower than expected effective tax rate of 16%…. …read more

Read more here::